FDA Approach On Warning Letters, Drug Approvals Could Change Post-Caroniao

 Industry attorneys suggest FDA warning letters will become more carefully worded and potentially easier to challenge on First Amendment grounds in the wake of the Second Circuit’s decision in the landmark off-label promotion case. FDA’s view of the evidence needed to demonstrate drug efficacy also could evolve. 

Purchase report here